New drug shows promise in early liver cancer trial
NCT ID NCT04358185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein that helps cancer spread.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Promising drug cocktail targets Hard-to-Treat liver cancer
- Virus therapy takes on liver cancer in major trial